Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus

Journal of the American Society of Nephrology

Volumn 14, Issue 7, 2003, Pages 1880-1888

  Artz, Marika A ^a   Boots, Johannes M M ^b   Ligtenberg, Gerry ^c   Roodnat, Joke I ^d   Christiaans, Maarten H L ^b   Vos, Pieter F ^c   Blom, Henk J ^a   Sweep, Fred C G J ^a   Demacker, Pierre N M ^a   Hilbrands, Luuk B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; APOLIPOPROTEIN B; CREATININE; CYCLOSPORIN; FIBRINOGEN; GLUCOSE; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN; TACROLIMUS; TRIACYLGLYCEROL;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETOGENESIS; DIET RESTRICTION; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OXIDATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCORING SYSTEM; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 10744219767     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000071515.27754.67     Document Type: Article

References (50)

1. Woo YM, Jardine AG, Clark AF, MacGregor MS, Bowman AW, Macpherson SG, Briggs JD, Junor BJ, McMillan MA, Rodger RS: Early craft function and patient survival following cadaveric renal transplantation. Kidney Int 55: 692-699, 1999
2. Lindholm A, Albrechtsen D, Frodin L, Tufveson G, Persson NH, Lundgren G: Ischemic heart disease - Major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 60: 451-457, 1995
3. Quaschning T, Mainka T, Nauck M, Rump LC, Wanner C, Kramer-Guth A: Immunosuppression enhances atherogenicity of lipid profile after transplantation. Kidney Int Suppl 71: S235-S237, 1999
4. Ligtenberg G, Hene RJ, Blankestijn PJ, Koomans HA: Cardiovascular risk factors in renal transplant patients: Cyclosporin A versus tacrolimus. J Am Soc Nephrol 12: 368-373, 2001
5. Apanay DC, Neylan JF, Ragab MS, Sgoutas DS: Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients. Transplantation 58: 663-669, 1994
6. Brown JH, Murphy BG, Douglas AF, Short CD, Bhatnagar D, Mackness MI, Hunt LP, Doherty CC, Durrington PN: Influence of immunosuppressive therapy on lipoprotein(a) and other lipoproteins following renal transplantation. Nephron 75: 277-282, 1997
7. Arnadottir M, Hultberg B, Vladov V, Nilsson-Ehle P, Thysell H: Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients. Transplantation 61: 509-512, 1996
8. Bostom AG, Gohh RY, Beaulieu AJ, Han H, Jacques PF, Selhub J, Dworkin L, Rosenberg IH: Determinants of fasting plasma total homocysteine levels among chronic stable renal transplant recipients. Transplantation 68: 257-261, 1999
9. van den Dorpel MA, Veld AJ, Levi M, ten Cate JW, Weimar W: Beneficial effects of conversion from cyclosporine to azathioprine on fibrinolysis in renal transplant recipients. Arterioscler Thromb Vasc Biol 19: 1555-1558, 1999
10. Bosmans JL, Holvoet P, Dauwe SE, Ysebaert DK, Chapelle T, Jurgens A, Kovacic V, Van Marck EA, De Broe ME, Verpooten GA: Oxidative modification of low-density lipoproteins and the outcome of renal allografts at 1 1/2 years. Kidney Int 59: 2346-2356, 2001
11. Dimeny E, Wahlberg J, Lithell H, Fellstrom B: Hyperlipidaemia in renal transplantation - Risk factor for long-term graft outcome. Eur J Clin Invest 25: 574-583, 1995
12. Peschke B, Scheuermann EH, Geiger H, Bolscher S, Kachel HG, Lenz T: Hypertension is associated with hyperlipidemia, coronary heart disease and chronic graft failure in kidney transplant recipients. Clin Nephrol 51: 290-295, 1999
13. McCune TR, Thacker-LR II, Peters TG, Mulloy L, Rohr MS, Adams PA, Yium J, Light JA, Pruett T, Gaber AO, Selman SH, Jonsson J, Hayes JM, Wright FH, Armata T, Blanton J, Burdick JF: Effects of tacrolimus on hyperlipidemia after successful renal transplantation: A Southeastern Organ Procurement Foundation multicenter clinical study. Transplantation 65: 87-92, 1998
14. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 25: S5-S20, 2002
15. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H. Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation 97: 1837-1847, 1998
16. Demacker PN, Veerkamp MJ, Bredie SJ, Marcovina SM, de Graaf J, Stalenhoef AF: Comparison of the measurement of lipids and lipoproteins versus assay of apolipoprotein B for estimation of coronary heart disease risk: A study in familial combined hyperlipidemia. Atherosclerosis 153: 483-490, 2000
17. Kleinveld HA, Hak-Lemmers HL, Stalenhoef AF, Demacker PN: Improved measurement of low-density-lipoprotein susceptibility to copper-induced oxidation: Application of a short procedure for isolating low-density lipoprotein. Clin Chem 38: 2066-2072, 1992
18. te-Poele-Pothoff MT, van den Berg M, Franken DG, Boers GH, Jakobs C, de Kroon IF, Eskes TK, Trijbels JM, Blom HJ: Three different methods for the determination of total homocysteine in plasma. Ann Clin Biochem 32: 20, 1995
19. Grebenschikov N, Geurts-Moespot A, De Witte H, Heuvel J, Leake R, Sweep F, Benraad T: A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-I) in breast tumor cytosols. Int J Biol Markers 12: 6-14, 1997
20. Rayyes OA, Wallmark A, Floren CH: Cyclosporine inhibits catabolism of low-density lipoproteins in HepG2 cells by about 25%. Hepatology 24: 613-619, 1996
21. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320: 915-924, 1989
22. McKeone BJ, Patsch JR, Pownall HJ: Plasma triglycerides determine low density lipoprotein composition, physical properties, and cell-specific binding in cultured cells. J Clin Invest 91: 1926-1933, 1993
23. Aviram M, Lund-Katz S, Phillips MC, Chait A: The influence of the triglyceride content of low density lipoprotein on the interaction of apolipoprotein B-100 with cells. J Biol Chem 263: 16842-16848, 1988
24. de Graaf J, Hak-Lemmers HL, Hectors MP, Demacker PN, Hendriks JC, Stalenhoef AF: Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 11: 298-306, 1991
25. Teng B, Sniderman AD, Soutar AK, Thompson GR: Metabolic basis of hyperapobetalipoproteinemia. Turnover of apolipoprotein B in low density lipoprotein and its precursors and subfractions compared with normal and familial hypercholesterolemia. J Clin Invest 77: 663-672, 1986
26. Venkiteswaran K, Sgoutas DS, Santanam N, Neylan JF: Tacrolimus, cyclosporine and plasma lipoproteins in renal transplant recipients. Transpl Int 14: 405-410, 2001
27. Varghese Z, Fernando RL, Turakhia G, Psimenou E, Brunton C, Fernando ON, Davenport A, Burns A, Sweny P, Powis SH, Moorhead JF: Oxidizability of low-density lipoproteins from Neoral and tacrolimus-treated renal transplant patients. Transplant Proc 30: 2043-2046, 1998
28. Boots JMM, van Duijnhoven EM, Christiaans MHL, Wolffenbuttel BHR, van Hooff JP: Glucose metabolism in renal transplant recipients on tacrolimus: The effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol 13: 221-227, 2002
29. Miles AM, Sumrani N, Horowitz R, Homel P, Maursky V, Markell MS, Distant DA, Hong JH, Sommer BG, Friedman EA: Diabetes mellitus after renal transplantation: As deleterious as non-transplant-associated diabetes? Transplantation 65: 380-384, 1998
30. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS: A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 63: 977-983, 1997
31. Mayer A: Chronic rejection and graft half-life: Five-year follow-up of the European tacrolimus multicenter renal study. Transplant Proc 34: 1491, 2002
32. Weir MR, Fink JC: Risk for posttransplant Diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis 34: 1-13, 1999
33. Boots JM, van Duijnhoven EM, Christiaans MH, Nieman FH, van Suylen RJ, van Hooff JP: Single-center experience with tacrolimus versus cyclosporine-Neoral in renal transplant recipients. Transpl Int 14: 370-383, 2001
34. van Duijnhoven EM, Christiaans MHL, Boots JMM, Nieman FHM, Wolffenbuttel BHR, van Hooff JP: Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression. J Am Soc Nephrol 13: 213-220, 2002
35. Duijnhoven EM, Boots JM, Christiaans MH, Wolffenbuttel BH, van Hooff JP: Influence of tacrolimus on glucose metabolism before and after renal transplantation: A prospective study. J Am Soc Nephrol 12: 583-588, 2001
36. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB: Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 258: 1183-1186, 1987
37. Fernandez-Miranda C, Morales JM, Porres A, Gomez-Gerique J, Guijarro C, Aranda JL, Andres A, Rodicio JLDPA: Increased lipoproteins and fibrinogen in chronic renal allograft dysfunction. Am J Nephrol 17: 445-449, 1997
38. Strauss BH, Lau HK, Bowman KA, Sparkes J, Chisholm RJ, Garvey MB, Fenkell LL, Natarajan MK, Singh I, Teitel JM: Plasma urokinase antigen and plasminogen activator inhibitor-I antigen levels predict angiographic coronary restenosis. Circulation 100: 1616-1622, 1999
39. Klein IHHT, Abrahams A, van Ede T, Hene RJ, Koomans HA, Ligtenberg G: Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation 73: 732-736, 2002
40. Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratzka LF, Houston-Miller N, Kris-Etherton P, Krumholz HM, LaRosa J, Ockene IS, Pearson TA, Reed J, Washington R, Smith SC, Jr: Primary prevention of coronary heart disease: guidance from Framingham: A statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. Circulation 97: 1876-1887, 1998
41. Massy ZA, Guijarro C, Wiederkehr MR, Ma JZ, Kasiske BL: Chronic renal allograft rejection: Immunologic and nonimmunologic risk factors. Kidney Int 49: 518-524, 1996
42. Isoniemi H, Nurminen M, Tikkanen MJ, von Willebrand E, Krogerus L, Ahonen J, Eklund B, Hockerstedt K, Salmela K, Hayry P: Risk factors predicting chronic rejection of renal allografts. Transplantation 57: 68-72, 1994
43. Pai R, Kirschenbaum MA, Kamanna VS: Low-density lipoprotein stimulates the expression of macrophage colony-stimulating factor in glomerular mesangial cells. Kidney Int 48: 1254-1262, 1995
44. Kamanna VS, Pai R, Ha H, Kirschenbaum MA, Roh DD: Oxidized low-density lipoprotein stimulates monocyte adhesion to glomerular endothelial cells. Kidney Int 55: 2192-2202, 1999
45. Quinn MT, Parthasarathy S, Fong LG, Steinberg D: Oxidatively modified low density lipoproteins: A potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci U S A 84: 2995-2998, 1987
46. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J: A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: Evidence for improved allograft survival at five years. Transplantation 73: 775-782, 2002
47. Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP: Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 62: 311-318, 2002
48. Baboolal K, Jones GA, Janezic A, Griffiths DR, Jurewicz WA: Molecular and structural consequences of early renal allograft injury. Kidney Int 61: 686-696, 2002
49. van Hooff JP, Boots JM, van Duijnhoven EM, Christiaans MH: Dosing and management guidelines for tacrolimus in renal transplant patients. Transplant Proc 31: 54S-57S, 1999
50. Margreiter R: Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: A randomised multicentre study. Lancet 359: 741-746, 2002